|
- Duoli SUN | University of Texas MD Anderson Cancer Center, Texas | MD . . .
Duoli SUN | Cited by 4,015 | of University of Texas MD Anderson Cancer Center, Texas (MD Anderson) | Read 52 publications | Contact Duoli SUN
- duoli sun - Retired - Home | LinkedIn
Research Scientist at MD Anderson Cancer Center · Experience: Home · Education: Texas Christian University · Location: Houston · 500+ connections on LinkedIn View duoli sun’s profile on
- Designing and developing S100P inhibitor 5-methyl cromolyn for . . . - PubMed
Analog 5-methyl cromolyn (C5OH) blocked S100P binding as well as the increases in NF-κB activity, cell growth, and apoptosis normally caused by S100P In vivo C5OH systemic delivery reduced NF-κB activity to a greater extent than cromolyn and at 10 times lesser dose (50 mg vs 5 mg)
- Duoli SUN Inventions, Patents and Patent Applications - Justia Patents . . .
Duoli SUN has filed for patents to protect the following inventions This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO)
- Angewandte Chemie International Edition - Wiley Online Library
Duoli Sun Dr Chemistry Department, University of Houston, Houston, TX 77204, USA, Fax: (+1) 713-743-2709 Search for more papers by this author
- Electron-transfer pathway for photoinduced Diels–Alder cycloadditions
Picosecond time-resolved spectroscopy reveals the one-electron transfer from excited (singlet) anthracene to the dienophile acceptor (resulting in the formation of anthracene cation radical and dienophile anion radical) as the critical step prior to cycloaddition
- Degrasyn-like symmetrical compounds: possible therapeutic agents for . . .
A series of degrasyn-like symmetrical compounds have been designed, synthesized, and screened against B cell malignancy (multiple myeloma, mantle cell lymphoma) cell lines
- Duoli Suns research works
Duoli Sun's 4 research works with 172 reads, including: POMHEX, a cell-permeable enolase inhibitor for collateral lethality targeting of ENO1-deleted glioblastoma
|
|
|